Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GSR | P00390 | 2/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL457153 | 1.00 | GRIK1 (0.44) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| Serine SCHEMBL21464138 | 0.83 | GRIK1 (0.50) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| SCHEMBL865368 | 0.82 | GRIK1 (0.46) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| SCHEMBL457154 | 0.82 | GRIK1 (0.46) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| Serine SCHEMBL5138193 | 0.81 | SLC1A1 (0.48) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| Serine SCHEMBL5011214 | 0.81 | SLC1A1 (0.48) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| Hydrochloric Acid SCHEMBL15265315 | 0.80 | GRIK1 (0.44) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| Serine SCHEMBL438419 | 0.79 | GRIK1 (0.48) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| Serine SCHEMBL21988617 | 0.79 | LMNA (0.48) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 | |
| Serine SCHEMBL3264996 | 0.79 | SLC1A1 (0.46) | GRIK1GRIK2SLC1A1PTGS1SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140127209-A1 | ANTIBODY DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2014-05-08 | — | — | US | claimed |
| EP-2640745-A2 | ANTIBODY DERIVATIVES | Allozyne, Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| WO-2012032181-A9 | ANTIBODY DERIVATIVES | ALLOZYNE, INC (US) | 2013-06-13 | — | — | WO | claimed |
| WO-2012032181-A2 | NOVEL ANTIBODY DERIVATIVES | ALLOZYNE, INC (US) | 2012-03-15 | — | — | WO | claimed |
| US-20240218069-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-B7H3 BINDING MOLECULES | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2024-07-04 | — | — | US | disclosed |
| CN-117751145-A | Bispecific antibodies comprising anti-B7H 3 binding molecules | 礼进生物医药科技（上海）有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230406950-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2023-12-21 | — | — | US | disclosed |
| CN-117015399-A | Bispecific antibodies comprising anti-CD 137 binding molecules | 礼进生物医药科技（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-4243869-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES | Lyvgen Biopharma Holdings Limited (KY) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023141611-A2 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2023-07-27 | — | — | WO | disclosed |
| CN-116057070-A | anti-CD 40 binding molecules and bispecific antibodies comprising same | 礼进生物医药科技（上海）有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230117565-A1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-20 | — | — | US | disclosed |
| EP-3240570-A1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | Dyax Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| CN-103261222-B | Antibody derivatives | 医疗免疫有限公司 | 2017-07-28 | — | — | CN | disclosed |
| US-20160194391-A1 | ANTIBODY DERIVATIVES | ALLOZYNE, INC. | 2016-07-07 | — | — | US | disclosed |
| WO-2016109774-A1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | DYAX CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| EP-2640745-A2 | ANTIBODY DERIVATIVES | Allozyne, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012032181-A9 | ANTIBODY DERIVATIVES | ALLOZYNE, INC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012032181-A2 | NOVEL ANTIBODY DERIVATIVES | ALLOZYNE, INC (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194391-A1 | ANTIBODY DERIVATIVES | IL23R, IL6, IL2 | GRIK1 4660/4885GRIK2 4278/4885SLC1A1 4250/4885 |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | IL23R, IL6, IL2 | GRIK1 4672/4885GRIK2 4291/4885SLC1A1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.